The Ohio State University Comprehensive Cancer Center (OSUCCC) is currently in its 29th year as an NCI-designated CCC and is now requesting continued federal support for the next five years. The OSUCCC named its 4th Director, Michael A. Caligiuri, M.D. in July, 2003 while retaining the former Center Director, Clara D. Bloomfield, M.D., as a Senior Advisor to the OSUCCC. The overall goal remains to reduce cancer morbidity and mortality through continued basic, translational and clinical research. The 183 OSUCCC members are currently served by 13 shared resources and are distributed among 6 Research Programs: Cancer Control, Experimental Therapeutics, Immunology, Molecular Biology and Cancer Genetics, Molecular Carcinogenesis and Chemoprevention and Viral Oncogenesis. Since the last competitive renewal, the OSUCCC has shown significant growth as demonstrated by: 1) the recruitment of more than 90 new cancer research faculty to OSU; 2) more than a 230% increase in patient accrual to investigator-initiated trials; 3) the addition of 6 new shared resources at an institutional investment of over $10.8 M; 4) a 144% increase in total NCI funding and a 65% increase in peer-reviewed funding. The OSUCCC has also seen tremendous growth in institutional commitment since 1999 as demonstrated by: 1) a new formal role for the OSUCCC Director within OSU, providing complete oversight of the University-wide cancer funding initiatives, opportunities and cancer grant submissions; 2) A seat on the eight-member Medical Center Executive Committee which meets every week with the Senior VP of Health Sciences to plan and evaluate the entire Health System's direction (cancer is the only discipline represented on this Committee); 3) a written commitment for the expansion of the Cancer Program facilities that will result in more than a four-fold increase over the current square footage under control of the OSUCCC Director at a cost of approximately $350 M; 4) interim laboratory and office space for recruitment until the new facility is constructed; 5) an additional $7.0 M of cash annually from OSU for research and infrastructure expansion; and 6) twenty senior faculty slots under the control of the OSUCCC Director, each provided with $100,000 of guaranteed salary in perpetuity. With these new resource commitments in place, the OSUCCC is poised for significant growth and expansion in the next 5 years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016058-30S2
Application #
7126643
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-12
Project End
2009-11-30
Budget Start
2004-12-01
Budget End
2005-11-30
Support Year
30
Fiscal Year
2005
Total Cost
$249,839
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Killian, Jackson A; Topiwala, Taha M; Pelletier, Alex R et al. (2018) FuSpot: a web-based tool for visual evaluation of fusion candidates. BMC Genomics 19:139
Sizemore, Gina M; Balakrishnan, Subhasree; Thies, Katie A et al. (2018) Stromal PTEN determines mammary epithelial response to radiotherapy. Nat Commun 9:2783
Zeng, Rong; Liu, Yi; Jiang, Zhao-Jing et al. (2018) EPB41L3 is a potential tumor suppressor gene and prognostic indicator in esophageal squamous cell carcinoma. Int J Oncol :
Kotlarek, Marta; Kubiak, Anna; Czetwerty?ska, Ma?gorzata et al. (2018) The rs2910164 Genetic Variant of miR-146a-3p Is Associated with Increased Overall Mortality in Patients with Follicular Variant Papillary Thyroid Carcinoma. Int J Mol Sci 19:
Li, Feng; Malli, Ahmad; Cruz-Monserrate, Zobeida et al. (2018) Confocal endomicroscopy and cyst fluid molecular analysis: Comprehensive evaluation of pancreatic cysts. World J Gastrointest Endosc 10:1-9
He, Huiling; Li, Wei; Yan, Pearlly et al. (2018) Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma. Thyroid 28:748-754
Moshiri, Jasmine; Kaur, Darpan; Hambira, Chido M et al. (2018) Identification of a Small Molecule Anti-biofilm Agent Against Salmonella enterica. Front Microbiol 9:2804
Serna, Vanida A; Wu, Xin; Qiang, Wenan et al. (2018) Cellular kinetics of MED12-mutant uterine leiomyoma growth and regression in vivo. Endocr Relat Cancer 25:747-759
Dabrowski, Konrad; Miller, Mackenzie (2018) Contested Paradigm in Raising Zebrafish (Danio rerio). Zebrafish 15:295-309
Krok-Schoen, Jessica L; Fisher, James L; Baltic, Ryan D et al. (2018) White-Black Differences in Cancer Incidence, Stage at Diagnosis, and Survival Among Older Adults. J Aging Health 30:863-881

Showing the most recent 10 out of 2602 publications